PATENT CLAIM ANALYSIS

Application Number: 15779611
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-12
Patent Classification: ["514", "327000"]

Abstract:
The present invention relates to an improved formulation of danirixin in its hydrobromide salt form. This improved formulation can be an aqueous intravenous formulation containing danirixin or a lyophilized pharmaceutical solid composition containing danirixin to be reconstituted to provide a solution for intravenous administration.

Claim (Index 31):
The method according to  claim 29 , wherein the composition has the amount of Table C below: TABLE C COMPOSITION Formula Unit Formula, (HBr lyophilized (mg/mL) Nominal Fill formulation) 2 mg/mL (mg/13 mL) Danirixin, HBr. \u20032.46 mg* 31.98 mg ACTIVE SUBSTANCE B-CYCLODEXTRIN \u200240.0 mg 520.0 mg SULFOBUTYLETHER, CAPTISOL\u2009\u00ae MANNITOL \u2003\u200950 mg 650.0 mg CITRIC ACID 0.655 mg 8.515 mg SODIUM CITRATE 0.555 mg 7.215 mg SODIUM HYDROXIDE QS QS HYDROCHLORIC QS QS ACID pH 3.9 \u2014 *QS refers to \u201cquantity sufficient\u201d to fill the vial to the nominal fill (or volume). *indicates 2 mg/mL that has been adjusted for the salt factor of 1.228 = 2.46 mg/mL

Metadata:
- Claim Count in Document: 38.0
- Percentile: 93.0
- Lexical Diversity: 1.39394
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14668683', '10553139', '13704145', '12370794', '16073580']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7217488259646189
- 35 USC 102 Novelty (BERT): 0.504131062702521
- Combined Prediction Score: 0.6999870496384091
- Mean Citation Score: 172.468098
- Max Citation Score: 174.8063
- Similarity Product: 108.26536782683728

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test